Effect of Aficamten on Cardiac Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The SEQUOIA-HCM CMR Trial

1 September 2024 (08:15 - 08:26)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor Ahmad Masri

Oregon Health & Science University Medical Group, Portland (United States of America)

7 More presentations in this session

Presentation thumbnail

Effect of Aficamten on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM

Doctor J. Spertus (Kansas City, US)

Presentation thumbnail

Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Doctor S. Hegde (Dallas, US)

Presentation thumbnail

Safety and Outcomes of Standard of Care Medications Withdrawal in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten in FOREST-HCM Trial

Doctor A. Masri (Portland, US)

Presentation thumbnail

Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis

Associate Professor M. Banovic (Belgrade, RS)

Presentation thumbnail

Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: A subanalysis from the DEDICATE-DZHK6 trial

Professor S. Bleiziffer (Bad Berka, DE)

Access the full session

Session thumbnail

Trial updates and other studies in hypertrophic cardiomyopathy and aortic stenosis

The Event

Event poster

ESC Congress 2024

1 September 2024 08:15 CET

You may be interested in

Congress Presentation

Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Congress Presentation

Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM an international multicenter phase 3 trial

Congress Presentation

Effect of Aficamten Compared with Metoprolol on Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy: A pre-specified analysis of MAPLE-HCM

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources